Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
PPMI’s principal investigator, Ken Marek, MD, and The Michael J. Fox Foundation’s Mark Frasier, PhD held the PPMI Progress Update: Available Data and Biosamples webinar, covering an overview of PPMI, some initial findings, and the process for accessing the PPMI clinical data, imaging data, and biospecimens. A recording of the webinar is now available.
Serum analysis data from Maria Teresa Pellecchia, MD of the University of Salerno is now live in the PPMI database. Qualified researchers can download this data at no cost.
PPMI and The Michael J. Fox Foundation are hosting a webinar which will cover available PPMI samples and data and the process for requesting both. The webinar will take place Monday, December 15, 12 to 1 p.m. ET. Learn more and register today.
Michael J. Fox has created an exclusive video thanking the PPMI volunteers and researchers for their exceptional contributions to Parkinson’s research.
PPMI has been actively collecting a wealth of biospecimens from the study participants, a group that has now grown to over 800 enrolled individuals. The samples are standardized, longitudinal, and available to qualified researchers conducting biomarker verification studies.